In March 2003 the OFT decided that Genzyme had infringed the UK Competition Act's Chapter II prohibition (the UK analogue of EC Article 82) by bundling its product with associated home care services, and by imposing a margin squeeze on competing firms [1]. Based on the case law and the OFT's published guidelines, this decision might appear at first glance to be a straightforward case of dominant firm abuse. But a closer analysis of the economic issues raises some interesting and as yet unanswered questions about the nature of dominant firms' obligations under competition law. The Facts Genzyme is a US-based global research-pharmaceutical company whose product portfolio includes Cerezyme, a drug used for the treatment of a rare medical condition known as Gaucher disease that affects
Share on
|
|
The UK Competition Authority imposes a £6.8 million fine for abusive bundling and margin squeeze (Healthcare at Home / Genzyme)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
